Last €12.02 EUR
Change Today +0.68 / 5.95%
Volume 0.0
I76 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 3:00 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (I76) Snapshot

Open
€11.25
Previous Close
€11.34
Day High
€12.02
Day Low
€11.25
52 Week High
12/19/14 - €12.02
52 Week Low
04/15/14 - €6.89
Market Cap
1.7B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
123.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IRONWOOD PHARMACEUTICALS INC (I76)

ironwood pharmaceuticals inc (I76) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (I76) Details

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company’s lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

534 Employees
Last Reported Date: 02/7/14
Founded in 1998

ironwood pharmaceuticals inc (I76) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $360.9K
Chief Scientific Officer, President of Resear...
Total Annual Compensation: $376.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $366.6K
Compensation as of Fiscal Year 2013.

ironwood pharmaceuticals inc (I76) Key Developments

Ironwood Pharmaceuticals Initiates Phase IIa Clinical Study of IW-9179 in Diabetic Gastroparesis

Ironwood Pharmaceuticals, Inc. announced that dosing has begun in a Phase IIa clinical study evaluating whether its investigational guanylate cyclase-C (GC-C) agonist, IW-9179, can provide symptomatic relief to patients with diabetic gastroparesis. Data are expected in the first half of 2016. The randomized, double-blind, placebo-controlled, multi-site Phase IIa clinical study is expected to enroll approximately 80 adult patients with diabetic gastroparesis. Patients will be randomized to receive IW-9179 or placebo orally once or twice daily for four weeks. The study design includes multiple exploratory endpoints, including patient-reported daily severity assessments of diabetic gastroparesis symptoms.

Ironwood Pharmaceuticals, Inc. Earns $15 Million Development Milestone Payment from Astellas Pharma Inc

Ironwood Pharmaceuticals, Inc. announced that it has earned a $15 million development milestone payment from Astellas Pharma Inc. This milestone was triggered by Astellas's enrollment of the first patient in a randomized, double-blind, placebo-controlled Phase III clinical trial of linaclotide in adult patients with irritable bowel syndrome with constipation (IBS-C) in Japan. Astellas expects to complete the Phase III trial in 2016. Ironwood and Astellas entered into a licensing agreement in 2009 to develop and commercialize linaclotide in Japan for the treatment of IBS-C, chronic constipation and other gastrointestinal conditions. Per the agreement, Astellas paid Ironwood a $30 million upfront licensing fee. In addition to the $15 million development milestone payment upon enrollment of the first patient in the Phase III trial, the agreement also includes additional development milestone payments that could total up to $30 million, consisting of $15 million upon filing for regulatory approval in Japan and $15 million upon receipt of approval. The agreement also provides for Ironwood to receive royalties which escalate based on sales volume. Astellas also plans to expand its development of linaclotide in Japan and is entering into a Phase II clinical trial with linaclotide in adults with chronic constipation. If approved, the same royalty terms would apply.

Ironwood Pharmaceuticals, Inc. Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation

Ironwood Pharmaceuticals, Inc. announced the initiation of a Phase III clinical trial in the U.S. evaluating a 72 mcg capsule of linaclotide to be taken once per day for the treatment of adults suffering from chronic idiopathic constipation (CIC). Linaclotide is currently approved by the U.S. Food and Drug Administration as a 145 mcg capsule to be taken once per day for the treatment of adults with CIC and as a 290 mcg capsule to be taken once per day for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Data from the Phase III trial of 72 mcg linaclotide are expected in 2016. The clinical trial is being conducted jointly by Ironwood and Actavis plc, Ironwood's co-development and co-promotion partner for linaclotide in the United States. The randomized, double-blind, placebo-controlled, multi-site Phase III clinical trial is expected to enroll approximately 1,200 adult patients with CIC. Patients with CIC have fewer than three spontaneous bowel movements per week, and they also may experience recurrent straining, lumpy or hard stools, and/or a sensation that their bowels are not fully empty. Patients will be randomized to receive 145 mcg of linaclotide once per day, 72 mcg of linaclotide once per day, or placebo once per day for 12 weeks. The primary objective of the trial is to determine the efficacy and safety of linaclotide 72 mcg in adult patients with CIC. The primary efficacy assessment is the percentage of patients who experience at least three complete spontaneous bowel movements (CSBMs) per week and an increase of at least one CSBM from baseline in the same week, and achieve both of these measures for nine out of 12 weeks (12-week CSBM Overall Responder).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I76:GR €12.02 EUR +0.68

I76 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $5.32 USD -0.10
Nektar Therapeutics $15.69 USD +0.075
Progenics Pharmaceuticals Inc $7.25 USD -0.095
Sucampo Pharmaceuticals Inc $13.57 USD +0.13
Theravance Inc $15.22 USD -0.005
View Industry Companies
 

Industry Analysis

I76

Industry Average

Valuation I76 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.5x
Price/Book 19.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit www.ironwoodpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.